IO Biotech to Announce Pivotal Phase 3 Trial Results on August 11, 2025.

IO Biotech will hold a conference call and webcast on August 11, 2025, to disclose the topline results of its Phase 3 trial of Cylembio, a cancer vaccine, in combination with pembrolizumab for unresectable or metastatic melanoma. The company's management team will discuss the results, which will be available on the IO Biotech website following the event.

IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for August 11, 2025, at 8:30 AM ET to reveal the topline results from its pivotal Phase 3 trial (IOB-013/KN-D18) of Cylembio, an investigational immune-modulatory cancer vaccine, in combination with KEYTRUDA® (pembrolizumab) versus KEYTRUDA® alone for first-line treatment of advanced melanoma.

The trial, which focuses on patients with unresectable or metastatic melanoma, will be discussed by the company's management team. The live event will be accessible via a webcast or teleconference. A replay will be available on the IO Biotech website following the event.

IO Biotech is developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. Cylembio, the lead candidate, has shown promising results in Phase 1/2 trials in combination with KEYTRUDA®, leading to a Breakthrough Therapy Designation from the US Food and Drug Administration for the treatment of advanced melanoma.

For further information, interested parties can visit the IO Biotech website at www.iobiotech.com or contact Maryann Cimino, Director of Investor Relations, at 617-710-7305 or mci@iobiotech.com.

References:
[1] https://www.stocktitan.net/news/IOBT/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-smndfr3pdv2n.html
[2] https://www.globenewswire.com/news-release/2025/08/10/3130545/0/en/IO-Biotech-to-Announce-Topline-Results-of-Pivotal-Phase-3-Trial-of-Cylembio-in-Combination-with-KEYTRUDA-pembrolizumab-as-a-First-Line-Treatment-for-Patients-with-Advanced-Melanoma.html